DR1
Protein Dr1
Also known as: NC2-BETA, NC2B, NC2B_HUMAN, NCB2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q01658
- Gene
- DR1
- Ensembl
- ENSG00000117505
- Chromosome
- 1
- Canonical length
- 176 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a TBP- (TATA box-binding protein) associated phosphoprotein that represses both basal and activated levels of transcription. The encoded protein is phosphorylated in vivo and this phosphorylation affects its interaction with TBP. This protein contains a histone fold motif at the amino terminus, a TBP-binding domain, and a glutamine- and alanine-rich region. The binding of DR1 repressor complexes to TBP-promoter complexes may establish a mechanism in which an altered DNA conformation, together with the formation of higher order complexes, inhibits the assembly of the preinitiation complex and controls the rate of RNA polymerase II transcription. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
176 residues, UniProt reviewed canonical sequence.
>Q01658|DR1
1 MASSSGNDDD LTIPRAAINK MIKETLPNVR VANDARELVV NCCTEFIHLI SSEANEICNK
61 SEKKTISPEH VIQALESLGF GSYISEVKEV LQECKTVALK RRKASSRLEN LGIPEEELLR
121 QQQELFAKAR QQQAELAQQE WLQMQQAAQQ AQLAAASASA SNQAGSSQDE EDDDDILocalizationUniProt · AlphaFold · HPA
Whether an antibody against DR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 56 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 56 nTPM
- testis: 52 nTPM
- skeletal muscle: 47 nTPM
- thymus: 44 nTPM
- lymph node: 41 nTPM
- tongue: 40 nTPM
Single-cell type
- late primary spermatocytes: 283 nCPM
- megakaryocytes: 185 nCPM
- basal keratinocytes: 149 nCPM
- neutrophil progenitors: 148 nCPM
- early spermatids: 148 nCPM
- late spermatids: 137 nCPM
Immune cell
- basophil: 96 nTPM
- eosinophil: 82 nTPM
- neutrophil: 63 nTPM
- T-reg: 57 nTPM
- myeloid DC: 56 nTPM
- intermediate monocyte: 53 nTPM
Brain region
- choroid plexus: 63 nTPM
- cerebellum: 38 nTPM
- hypothalamus: 36 nTPM
- thalamus: 35 nTPM
- white matter: 34 nTPM
- spinal cord: 34 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.37
- gnomAD pLI
- 0.92
- gnomAD missense Z
- 2.23
- DepMap mean gene effect
- -0.88
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of transcription by RNA polymerase II
- regulation of cell cycle
- regulation of cell division
- regulation of DNA-templated transcription
- regulation of embryonic development
- regulation of transcription by RNA polymerase II
- RNA polymerase II preinitiation complex assembly
Molecular functions
- DNA binding
- protein heterodimerization activity
- RNA polymerase II general transcription initiation factor activity
- TBP-class protein binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Transcription factor CBF/NF-Y/archaeal histone domain
- Histone-fold
- Histone-like transcription factor (CBF/NF-Y) and archaeal histone
- Negative cofactor 2 complex subunit beta
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DR1 as an antibody target. Whether an autoantibody or antibody against DR1 could matter depends on whether native DR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DR1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...